Navigation Links
Data Available From Erbitux Phase III Study in First-Line Treatment,of Advanced Lung Cancer

Although the company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions it can give no assurance that its expectations will be achieved. Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the company's ability to control or predict. Important factors that may cause actual results to differ materially and could impact the company and the statements contained in this news release can be found in the company's filings with the Securities and Exchange Commission, including quarterly reports on Form 10-Q, current reports on Form 8-K and annual reports on Form 10-K. For forward-looking statements in this news release, the company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise.

About Bristol-Myers Squibb

Bristol-Myers Squibb is dedicated to the discovery, development and exhaustive exploration of innovative cancer fighting therapies designed to extend and enhance the lives of patients living with cancer. More than 40 years ago, Bristol-Myers Squibb built a unified vision for the future of cancer treatment. With expertise, dedication and resolve, that vision led to the development of a diverse global portfolio of anti-cancer therapies that are an important cornerstone of care today. Hundreds of scientists at Bristol- Myers Squibb's Pharmaceutical Research Institute are studying ways to improve current cancer treatments and identify better, more effective medicines for the future.

Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Positive Results Prompt US National Cancer Institute to Make Glivec Available to Patients in Post-Surgical GIST Study
2. Positive Results Prompt US National Cancer Institute to Make Gleevec Available To Patients in Post-Surgical Gist Study
3. Data Available from Erbitux Phase III Study in First-Line Treatment of Advanced Pancreatic Cancer
4. Survival Data Available From Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer
5. Survival Data Available from Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer
6. Extensive Clinical Data on Erbitux Presented at the 2007 ASCO Annual Meeting
7. Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of Erbitux for Colorectal and Head and Neck Cancer Patients
8. Randomized Phase III Trial Showed Erbitux Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients
9. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:12/1/2008)...ewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (...t , one of the world,s leading medical journals, r...egulator, experimental compound tasimelteon (VEC-1...titled "Melatonin agonist tasimelteon (VEC-162) fo...andomised controlled multicentre trials." Results ...
(Date:12/1/2008)...swire/ -- Roche announced today that a,comparativ...ived pain and,discomfort associated with blood gl...toring systems and lancing devices were deemed lea...ll, the ACCU-CHEK Aviva and ACCU-CHEK Compact,Plu...EK Multiclix, ACCU-CHEK,Softclix and ACCU-CHEK So...
(Date:12/1/2008)...he best policy , , ROCHESTER, Minn., Dec. ... Clinic finds the use of the drug therapy etanerce... acute inflammation of the liver caused by excessi...y are published in the December issue of Gastroen... , VIDEO ALERT: Additional audio and video res...
(Date:12/1/2008)...d for Tuesday, December 9 at 11:00 am ET to Discus...H SAN FRANCISCO, Calif., Dec. 1 /PRNewswire-Firs... SNSS ), a biopharmaceutical company focused on th...y therapeutics, today announced new data from its ...L) will be presented during the 50th American Soci...
Breaking Medicine Technology:Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 2Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 3Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 4Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful 2Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful 3Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 2Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 3Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 2Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 3ASPH and APHA Collaborate to Shore up the Public Health Workforce Pipeline 3A 27906 1ASPH and APHA Collaborate to Shore up the Public Health Workforce Pipeline 3A 27906 2ASPH and APHA Collaborate to Shore up the Public Health Workforce Pipeline 3A 27906 3Bright Horizons Congratulates 76 Clients Named to Working Mothers 100 Best 27901 1Bright Horizons Congratulates 76 Clients Named to Working Mothers 100 Best 27901 2Premier Research Honored as Clinical Research Team of the Year at 2008 GCPj Awards 3355 1Premier Research Honored as Clinical Research Team of the Year at 2008 GCPj Awards 3355 2Scientists unveil mechanism for up and down in plants 5605 1Scientists unveil mechanism for up and down in plants 5605 2
...etary DNA delivery technology enables sustained,In...es,atherosclerosis progression in mouse model of h..., 2007 - Research conducted,at Cleveland Clinic an...ology,s 58th Annual Scientific Session showed that...inflammatory protein,interferon-beta (IFN-beta) us...
...oadministered with statins for only five weeks at,...hieved with,statins alone, with similarly favorabl... and CARLSBAD, Calif., March 26, 2007,/PRNewswire-... new,results from its Phase 2 clinical trial of IS...day at the of Cardiology,Annual Scientific Session...
Other Medicine Technology:Interferon Beta DNA Treatment Delivered with Ichor Technology,Reduces Atherosclerosis Progression in Mice 2Interferon Beta DNA Treatment Delivered with Ichor Technology,Reduces Atherosclerosis Progression in Mice 3Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 2Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 3Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 4Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 5Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 6Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 7Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 8Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL 9
(Date:12/2/2008)...N, China, Dec. 2 /PRNewswire-Asia-FirstCall/ -- Ch..." or "the Company") (Nasdaq: CSKI ), a leading,...over-the-counter drugs in,the People,s Republic o...Stanley) Hao was appointed Chief Financial Officer...,s Board of Directors. He replaces Yu-kun Zhang, ...
(Date:12/2/2008)...BURGH, Dec. 2 Mylan Inc....ubsidiary, Mylan Pharmaceuticals Inc., have entere...aceuticals Corp., Novartis,Corp. and Novartis Int...neric,version of Novartis, Femara(R). , My...ted: "We are very,pleased to have reached this ag...
(Date:12/2/2008)...NVILLE, Calif., Dec. 2 In response...n A Toxicity, Frequent Respiratory Infections, and...ovember 11th by 16 well known supplement experts, ... oil products pose no threat or compromise to cons...solutions that are low in natural Vitamin A. Accor...
(Date:12/2/2008)... SPEAK to collect and dissemin... Bellevue, Wash. (PRWEB) December ...ced the launch of a new initiative to focus public...eness . The official kick-off of SPEAK will occur ...acists (ASHP) 2008 Midyear Clinical Meeting, to be...
Breaking Medicine News(10 mins):Health News:China Sky One Medical, Inc. Appoints Yu-bo Hao as CFO 2Health News:China Sky One Medical, Inc. Appoints Yu-bo Hao as CFO 3Health News:Mylan Announces Settlement Agreement with Novartis Related to Femara(R) First- to-File Opportunity 2Health News:Nordic Naturals Offers Cod Liver Oil Solutions in Response to Recent Vitamin A and Vitamin D Controversy 2Health News:Pharmacy OneSource Launches SPEAK Initiative to Promote Medication Safety Awareness 2
...ave limited benefit in the first-line treatment of...// according to a report in the April issue of Arc...rnals. However, a second report in the same issue ...may be effective in patients with another ulcer-ca...
...n (FDA) is alerting consumers to possible serious ...aminated with a deadly bacterium, Clostridium botu...lly fatal illness. The olives are made by Charlie ... and are being recalled by the manufacturer. No il...
...for liver cancer, says a US study. Using DNA isol... researchers at Columbia University's Mailman Scho...rly detection of liver cancer, says the study publ...of Clinical Cancer Research. The scientists exami...
...ke is an effective way of identifying prostate can...teoporosis, according to a research.// Researcher... Barcelona, Spain, looked at a cross-section of 37...t were receiving androgen-deprivation therapy (ADT...
Other Medicine News:Health News:Clinical Studies Evaluate Potential Treatments for Mouth Ulcers 2Health News:Clinical Studies Evaluate Potential Treatments for Mouth Ulcers 3Health News:FDA Urgently Warns Consumers About Health Risks of Potentially Contaminated Olives 2Health News:Blood DNA Predicts Liver Cancer Early 2Health News:Measuring Calcium Intake Help to Identify Osteoporosis in Prostate Cancer Patient 2
...ducts are offered as 1-piece or modular, in regula...ay be customized with handles of choice and other ...ts. Many standard patterns are available from Medi...ivery times. , Please Note: Individual instrumen...
...ducts are offered as 1-piece or modular, in regula...ay be customized with handles of choice and other ...ts. Many standard patterns are available from Medi...ivery times. , Please Note: Individual instrumen...
...ducts are offered as 1-piece or modular, in regula...ay be customized with handles of choice and other ...ts. Many standard patterns are available from Medi...ivery times. , Please Note: Individual instrumen...
The Featured Products are kept in stock at Mediflex and are offered as 1-piece or modular in regular or extra long lengths. All come equipped with insulation, flush ports, rotating shafts, ratchets (
Medicine Products: